Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Multicenter retrospective study of trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) for vulnerable patients with pretreated metastatic colorectal cancer (mCRC): WJOG14520G (TWILIGHT).
Authors
Seiichiro Mitani
Kindai University Faculty of Medicine, Sayama-Shi, Japan;
Seiichiro Mitani , Yosuke Kito , Hisato Kawakami , Shinichi Nishina , Toshihiko Matsumoto , Takao Tsuzuki , Yudai Shinohara , Hozumi Shimokawa , Ryosuke Kumanishi , Takashi Ohta , Shinya Kimura , Takeshi Kawakami , Tomohiro Nishina , Hiroko Hasegawa , Kohei Akiyoshi , Yasutaka Chiba , Kentaro Yamazaki , Shuichi Hironaka , Kei Muro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000044136
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 121)
DOI
10.1200/JCO.2023.41.4_suppl.121
Abstract #
121
Poster Bd #
F18
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2018 Gastrointestinal Cancers Symposium
Safety for trifluridine/tipiracil (TAS-102) with bevacizumab combination in patients with refractory metastatic colorectal cancer in real-world clinical practice: The single-institutional experience.
First Author: Kayo Yasuda
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world treatment patterns and unmet need in patients with previously treated metastatic colorectal cancer that is not MSI-H or dMMR.
First Author: Kaushal Desai